Hypoglycemic unawareness monitoring tools -
Prevalence of hypoglycemia unawareness in patients with type 1 diabetes. Pediatr Diabet. Geddes J , Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes.
Diabet Med. Schopman JE , Geddes J, Frier BM. Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulin-treated type 2 diabetes. Diabetes Res Clin Pract. Cryer PE. The barrier of hypoglycemia in diabetes. Miura J , Kajiura M, Hoshina S, Kobayashi H, Uchigata Y.
The investigation of risk factor for the hypoglycemia unawareness in patients with type 1 diabetes using CGMS. Pambianco GL , Costacou T, Orchard TJ.
Does hypoglycemia unawareness HU differ by gender in type 1 diabetes T1D? Schouwenberg BJ , Veldman BA, Spiering W, Coenen MJ, Franke B, Tack CJ, de Galan BE, Smits P. The Arg16Gly variant of the beta2-adrenergic receptor predisposes to hypoglycemia unawareness in type 1 diabetes mellitus.
Pharmacogenet Genomics. Sejling AS , Kjaer TW, Pedersen-Bjergaard U, Remvig LS, Larsen A, Nielsen MN, Tarnow L, Thorsteinsson B, Juhl CB. The effect of recurrent hypoglycaemia on cerebral electrical activity in patients with type 1 diabetes and hypoglycaemia unawareness.
Dagogo-Jack S , Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Fanelli C , Pampanelli S, Epifano L, Rambotti AM, Di Vincenzo A, Modarelli F, Ciofetta M, Lepore M, Annibale B, Torlone E.
Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM.
Reno CM , Litvin M, Clark AL, Fisher SJ. Defective counterregulation and hypoglycemia unawareness in diabetes: mechanisms and emerging treatments. Endocrinol Metab Clin North Am. Ramanathan R , Cryer PE. Adrenergic mediation of hypoglycemia-associated autonomic failure.
Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med. Banarer S , Cryer PE. Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia.
McGregor VP , Banarer S, Cryer PE. Elevated endogenous cortisol reduces autonomic neuroendocrine and symptom responses to subsequent hypoglycemia. Am J Physiol Endocrinol Metab. Davis SN , Shavers C, Davis B, Costa F.
Prevention of an increase in plasma cortisol during hypoglycemia preserves subsequent counterregulatory responses. J Clin Invest. Davis SN , Shavers C, Costa F, Mosqueda-Garcia R.
Role of cortisol in the pathogenesis of deficient counterregulation after antecedent hypoglycemia in normal humans. Raju B , McGregor VP, Cryer PE. Cortisol elevations comparable to those that occur during hypoglycemia do not cause hypoglycemia-associated autonomic failure. Goldberg PA , Weiss R, McCrimmon RJ, Hintz EV, Dziura JD, Sherwin RS.
Antecedent hypercortisolemia is not primarily responsible for generating hypoglycemia-associated autonomic failure. McCrimmon RJ , Song Z, Cheng H, McNay EC, Weikart-Yeckel C, Fan X, Routh VH, Sherwin RS.
Corticotrophin-releasing factor receptors within the ventromedial hypothalamus regulate hypoglycemia-induced hormonal counterregulation.
Caprio S , Gerety G, Tamborlane WV, Jones T, Diamond M, Jacob R, Sherwin RS. Opiate blockade enhances hypoglycemic counterregulation in normal and insulin-dependent diabetic subjects. Am J Physiol.
Vele S , Milman S, Shamoon H, Gabriely I. Opioid receptor blockade improves hypoglycemia-associated autonomic failure in type 1 diabetes mellitus. J Clin Endocrinol Metab. Milman S , Leu J, Shamoon H, Vele S, Gabriely I.
Magnitude of exercise-induced β-endorphin response is associated with subsequent development of altered hypoglycemia counterregulation. Seaquist ER , Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
Zammitt NN , Warren RE, Deary IJ, Frier BM. Delayed recovery of cognitive function following hypoglycemia in adults with type 1 diabetes: effect of impaired awareness of hypoglycemia.
Puente EC , Silverstein J, Bree AJ, Musikantow DR, Wozniak DF, Maloney S, Daphna-Iken D, Fisher SJ. Recurrent moderate hypoglycemia ameliorates brain damage and cognitive dysfunction induced by severe hypoglycemia.
Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med. Cranston I , Reed LJ, Marsden PK, Amiel SA. Changes in regional brain 18 F-fluorodeoxyglucose uptake at hypoglycemia in type 1 diabetic men associated with hypoglycemia unawareness and counter-regulatory failure.
Dunn JT , Cranston I, Marsden PK, Amiel SA, Reed LJ. Attenuation of amydgala and frontal cortical responses to low blood glucose concentration in asymptomatic hypoglycemia in type 1 diabetes: a new player in hypoglycemia unawareness? Mangia S , Tesfaye N, De Martino F, Kumar AF, Kollasch P, Moheet AA, Eberly LE, Seaquist ER.
Hypoglycemia-induced increases in thalamic cerebral blood flow are blunted in subjects with type 1 diabetes and hypoglycemia unawareness. J Cereb Blood Flow Metab. Tesfaye N , Nangia S, De Martino F, Kumar A, Moheet A, Iverson E, Eberly LE, Seaquist ER.
Hypoglycemia-induced increases in cerebral blood flow CBF are blunted in subjects with type 1 diabetes TID and hypoglycemia unawareness HU.
Criego AB , Tkac I, Kumar A, Thomas W, Gruetter R, Seaquist ER. Brain glucose concentrations in patients with type 1 diabetes and hypoglycemia unawareness.
J Neurosci Res. Oz G , Kumar A, Rao JP, Kodl CT, Chow L, Eberly LE, Seaquist ER. Human brain glycogen metabolism during and after hypoglycemia. Canada SE , Weaver SA, Sharpe SN, Pederson BA. Brain glycogen supercompensation in the mouse after recovery from insulin-induced hypoglycemia.
Öz G , Tesfaye N, Kumar A, Deelchand DK, Eberly LE, Seaquist ER. Brain glycogen content and metabolism in subjects with type 1 diabetes and hypoglycemia unawareness.
Gulanski BI , De Feyter HM, Page KA, Belfort-DeAguiar R, Mason GF, Rothman DL, Sherwin RS. Increased brain transport and metabolism of acetate in hypoglycemia unawareness.
De Feyter HM , Mason GF, Shulman GI, Rothman DL, Petersen KF. Increased brain lactate concentrations without increased lactate oxidation during hypoglycemia in type 1 diabetic individuals. Moheet A , Emir UE, Terpstra M, Kumar A, Eberly LE, Seaquist ER, Öz G. Initial experience with seven tesla magnetic resonance spectroscopy of hypothalamic GABA during hyperinsulinemic euglycemia and hypoglycemia in healthy humans.
Magn Reson Med. Chan O , Cheng H, Herzog R, Czyzyk D, Zhu W, Wang A, McCrimmon RJ, Seashore MR, Sherwin RS. Increased GABAergic tone in the ventromedial hypothalamus contributes to suppression of counterregulatory responses after antecedent hypoglycemia.
Chan O , Paranjape S, Czyzyk D, Horblitt A, Zhu W, Ding Y, Fan X, Seashore M, Sherwin R. Increased GABAergic output in the ventromedial hypothalamus contributes to impaired hypoglycemic counterregulation in diabetic rats. Gold AE , MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia.
Choudhary P , Geddes J, Freeman JV, Emery CJ, Heller SR, Frier BM. Frequency of biochemical hypoglycaemia in adults with Type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring.
Gerstein HC , Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH.
Effects of intensive glucose lowering in type 2 diabetes. Zoungas S , Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S. Severe hypoglycemia and risks of vascular events and death.
Seaquist ER , Miller ME, Bonds DE, Feinglos M, Goff DC, Peterson K, Senior P. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Jacobson AM , Musen G, Ryan CM, Silvers N, Cleary P, Waberski B, Burwood A, Weinger K, Bayless M, Dahms W.
Long-term effect of diabetes and its treatment on cognitive function. Reichard P , Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Gold AE , MacLeod KM, Deary IJ, Frier BM. Hypoglycemia-induced cognitive dysfunction in diabetes mellitus: effect of hypoglycemia unawareness.
Physiol Behav. Bolo NR , Musen G, Jacobson AM, Weinger K, McCartney RL, Flores V, Renshaw PF, Simonson DC. Brain activation during working memory is altered in patients with type 1 diabetes during hypoglycemia.
Smith CB , Choudhary P, Pernet A, Hopkins D, Amiel SA. Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes: evidence from a clinical audit. Graveling AJ , Frier BM.
Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes: evidence from a clinical audit: response to Smith et al. Ly TT , Gallego PH, Davis EA, Jones TW.
Impaired awareness of hypoglycemia in a population-based sample of children and adolescents with type 1 diabetes. Hannonen R , Tupola S, Ahonen T, Riikonen R. Neurocognitive functioning in children with type-1 diabetes with and without episodes of severe hypoglycaemia.
Dev Med Child Neurol. Northam EA , Anderson PJ, Jacobs R, Hughes M, Warne GL, Werther GA. Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset.
Ho MS , Weller NJ, Ives FJ, Carne CL, Murray K, Vanden Driesen RI, Nguyen TP, Robins PD, Bulsara M, Davis EA. Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus. J Pediatr. Golden MP , Ingersoll GM, Brack CJ, Russell BA, Wright JC, Huberty TJ. Longitudinal relationship of asymptomatic hypoglycemia to cognitive function in IDDM.
Perantie DC , Lim A, Wu J, Weaver P, Warren SL, Sadler M, White NH, Hershey T. Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus. Pediatr Diabetes. Chico A , Vidal-Ríos P, Subirà M, Novials A.
The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control.
Hay LC , Wilmshurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring.
Diabetes Technol Ther. Desouza C , Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring.
Tanenberg RJ , Newton CA, Drake AJ. Johnston SS , Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes.
Miller DR , Fincke G, Lafrance JP, Palnati M, Shao Q, Zhang Q, Fonseca V, Riddle M, Vijan S, Christiansen CI. Hypoglycaemia and risk of myocardial infarction in US veterans with diabetes.
Holstein A , Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes. Amiel SA , Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Marrett E , Radican L, Davies MJ, Zhang Q. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study.
BMC Res Notes. Whitmer RA , Karter AJ, Yaffe K, Quesenberry CP, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. Allen KV , Frier BM. Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention. Alagiakrishnan K , Mereu L.
Approach to managing hypoglycemia in elderly patients with diabetes. Postgrad Med. Bruce DG , Casey GP, Grange V, Clarnette RC, Almeida OP, Foster JK, Ives FJ, Davis TM.
Cognitive impairment, physical disability and depressive symptoms in older diabetic patients: the Fremantle Cognition in Diabetes Study. Bree AJ , Puente EC, Daphna-Iken D, Fisher SJ. Diabetes increases brain damage caused by severe hypoglycemia.
Abbaszadeh Ahranjani S , Tabatabaei-Malazy O, Pajouhi M. Diabetes in old age, a review. Iranian J Diabetes and Lipid Disorders. Aung PP , Strachan MW, Frier BM, Butcher I, Deary IJ, Price JF. Severe hypoglycaemia and late-life cognitive ability in older people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study.
Budnitz DS , Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans.
Evers IM , ter Braak EW, de Valk HW, van Der Schoot B, Janssen N, Visser GH. Risk indicators predictive for severe hypoglycemia during the first trimester of type 1 diabetic pregnancy. Nielsen LR , Pedersen-Bjergaard U, Thorsteinsson B, Johansen M, Damm P, Mathiesen ER.
Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control. Robertson H , Pearson DW, Gold AE. Severe hypoglycaemia during pregnancy in women with Type 1 diabetes is common and planning pregnancy does not decrease the risk.
Rossi G , Lapaczewski P, Diamond MP, Jacob RJ, Shulman GI, Sherwin RS. Inhibitory effect of pregnancy on counterregulatory hormone responses to hypoglycemia in awake rat. Rosenn BM , Miodovnik M, Khoury JC, Siddiqi TA. Counterregulatory hormonal responses to hypoglycemia during pregnancy.
Obstet Gynecol. Ringholm L , Pedersen-Bjergaard U, Thorsteinsson B, Damm P, Mathiesen ER. Hypoglycaemia during pregnancy in women with Type 1 diabetes. Heller S , Damm P, Mersebach H, Skjøth TV, Kaaja R, Hod M, Durán-García S, McCance D, Mathiesen ER. Hypoglycemia in type 1 diabetic pregnancy: role of preconception insulin aspart treatment in a randomized study.
Barendse S , Singh H, Frier BM, Speight J. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in Type 2 diabetes: a narrative review. Davis RE , Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes.
Curr Med Res Opin. Williams SA , Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Lundkvist J , Berne C, Bolinder B, Jönsson L.
The economic and quality of life impact of hypoglycemia. Eur J Health Econ. Fidler C , Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs.
J Med Econ. Gold AE , Deary IJ, Frier BM. Hypoglycaemia and non-cognitive aspects of psychological function in insulin-dependent type 1 diabetes mellitus IDDM.
Strachan MW , Deary IJ, Ewing FM, Frier BM. Recovery of cognitive function and mood after severe hypoglycemia in adults with insulin-treated diabetes.
King P , Kong MF, Parkin H, Macdonald IA, Tattersall RB. Well-being, cerebral function, and physical fatigue after nocturnal hypoglycemia in IDDM. Ritholz MD , Jacobson AM.
Living with hypoglycemia. J Gen Intern Med. Eadington DW , Frier BM. Type 1 diabetes and driving experience: an eight-year cohort study. Lave LB , Songer TJ, LaPorte RE. Should persons with diabetes be licensed to drive trucks?
Risk Anal. Cox DJ , Kovatchev B, Vandecar K, Gonder-Frederick L, Ritterband L, Clarke W. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.
More topics Part 3: CCMTA Medical Standards with B. Specific Guidelines 1 - Introduction 2 - Medical conditions at a glance 3 - Cardiovascular disease and disorder 4 - Cerebrovascular disease 5 - Chronic renal disease 6 - Cognitive impairment Including dementia 7 - Diabetes and hypoglycemia 8 - General debility and lack of stamina 9 - Hearing loss 10 - Intracranial tumours 11 - Musculoskeletal conditions 12 - Neurological disorder 13 - Peripheral vascular diseases 14 - Psychiatric disorders 15 - Drugs, alcohol and driving 16 - Respiratory diseases 17 - Seizures and epilepsy 18 - Sleep disorders 19 - Syncope 20 - Traumatic brain injury 21 - Vestibular disorders 22 - Vision impairments.
Diabetes, hypoglycemia and medical fitness to drive. Type 1 diabetes Type 1 diabetes can occur at any age, but it primarily appears before age Type 2 diabetes Type 2 diabetes usually occurs in individuals over the age of Those with type 2 diabetes treated with insulin secretagogues oral medications that stimulate the secretion of insulin or metformin an oral medication that enhances the effect of insulin also may experience hypoglycemia, although the frequency with this treatment is lower than with insulin Hypoglycemia may occur for a number of reasons, including reduced food intake, unusual level of physical exertion, and alteration of insulin dose.
Hypoglycemia can result in two types of symptoms, neurogenic autonomic and neuroglycopenic. Neuroglycopenic symptoms of hypoglycemia Neuroglycopenic symptoms are the direct result of impaired brain function due to low glucose levels. Hypoglycemia unawareness Another complicating factor is hypoglycemia unawareness, which is the inability to recognize the autonomic symptoms of hypoglycemia or a failure of such warning signs to occur prior to impaired brain function.
Severe hypoglycemia Severe hypoglycemia is commonly defined as hypoglycemia that requires outside intervention to abort, or that produces an alteration in level of consciousness or loss of consciousness.
Diabetes is somewhat more prevalent in males, and the overall prevalence of diabetes increases with age, as shown in the figure below. Hypoglycemia A study of people with type 1 diabetes conducted in estimated that the incidence of mild hypoglycemia hypoglycemia for which a person is able to treat themselves to be 28 episodes per person per year.
While research has established clear links between diabetes, hypoglycemia and motor vehicle crashes, the variable results of these studies indicate that decisions about driving should be based on assessment of individual medical history and circumstances including: Treatment modality Incidence of hypoglycemia Incidence of hypoglycemia unawareness, and Presence of chronic complications of diabetes 7.
metformin, or Oral medication - insulin secretagogues i. glyburide, diamicron, etc National Standard All drivers eligible for any licence class if: Has good understanding if their condition Routinely follows their physicians instructions about diet, medication, glucose, glucose monitoring and hypoglycaemia prevention Conditions for maintaining a licence are met BC Guidelines RoadSafetyBC will not generally request further information.
For Non-Commercial Drivers, if blood glucose levels and treatment are not stable, RoadSafetyBC will re-assess annually until levels and treatment are stable. If blood glucose levels and treatment are stable, RoadSafetyBC will re-assess every five years or in accordance with the schedule for age related re-assessment Information from health care providers Description of treatment Rationale Drivers with diabetes who are not treated with insulin or insulin secretagogues are at little or no risk for hypoglycemia.
Because diabetes is a progressive condition, these drivers must remain under medical supervision and undergo a reassessment at the discretion of the authority.
Drivers who begin insulin therapy are required to report because of the significant increase in risk for hypoglycemia associated with insulin therapy.
The requirement to report is intended to ensure that drivers on insulin therapy meet the more stringent driver fitness standards and conditions for driving. Although there is some increased risk of hypoglycemia from the use of insulin secretagogues, the risk remains less than the risk from insulin therapy 7.
If blood glucose levels and treatment are stable, RoadSafetyBC will re-assess every five years, or in accordance with the schedule for age-related re-assessment Information from health care providers Description of treatment Opinion of treating physician whether the driver understands their diabetic condition and the close interrelationship between insulin and diet and exercise Rationale Drivers with diabetes who are treated with insulin therapy are at risk for hypoglycemia.
In addition to the conditions regarding how to avoid severe hypoglycemia while driving that apply to drivers treated with insulin secretagogues, there are additional conditions for checking and monitoring blood glucose. These conditions are based on guidelines published by Diabetes Canada.
This is due to both their high level of driving exposure and to the nature of the driving task, which may make it more difficult for them to manage their blood glucose The standard is focused on ensuring that these drivers have stable blood glucose levels and that they understand their condition and are able to effectively monitor and manage their blood glucose Restrictions No restrictions required 7.
For episode greater than 6 months - Driver fitness determinations can be made by adjudicators If further information is required, RoadSafetyBC may request: Additional information from the treating physician Conditions for maintaining licence Must test blood glucose immediately before driving and approximately every hour while driving Does not drive until at least 40 minutes after successful treatment of hypoglycemia and blood glucose has increased to at least 5.
Must refrain from driving immediately, and notify their health-care provider as soon as possible Reassessment RoadSafetyBC will re-assess as recommended by the treating physician.
At that time, if the treating physician indicates that there have been no episodes of severe hypoglycemia within the past six months, the application guidelines for private drivers with diabetes will apply Information from health care providers Date of the hypoglycemic episode Opinion of treating physician whether stable glycemic control has been re-established Must refrain from driving immediately, and notify their health-care provider as soon as possible Rationale Severe hypoglycemia indicates a lack of glycemic control and the potential for further hypoglycemic episodes.
Once control is re- established and driving resumes, more stringent glucose monitoring conditions are required temporarily to mitigate the increased risk of hypoglycemia 7. For episode greater than 6 months - Driver fitness determinations will be made by adjudicators. If further information is required, RoadSafetyBC may request: Additional information from the treating physician Conditions for maintaining licence Must test blood glucose immediately before driving and approximately every hour while driving Does not drive until at least 40 minutes after successful treatment of hypoglycemia and blood glucose has increased to at least 5.
Must refrain from driving immediately, and notify their health-care provider as soon as possible Reassessment RoadSafetyBC will re-assess in one year. At that time, if the treating physician indicates that there have been no further episodes of hypoglycemia unawareness within the past year, the conditions listed above will be removed and the applicable guidelines for private drivers with diabetes will apply Information from health care providers Date of the episode Opinion of treating physician whether glycemic awareness has been regained Opinion of treating physician whether the driver has stable glycemic control Rationale Hypoglycemia unawareness greatly increases the risk for hypoglycemia while driving.
This standard requires that glycemic awareness be re-established before driving resumes. Once awareness and glucose stability are re-established, more stringent glucose monitoring guidelines are required temporarily to mitigate the increased risk of hypoglycemia 7.
At that time, if the treating physician indicates that there have been no further episodes of hypoglycemia unawareness within the past year, the conditions noted above will be removed and the applicable guidelines for private drivers with diabetes will apply Information from health care providers Date of the last episode Opinion of treating physician whether stable glycemic control has been re-established Opinion of treating physician whether driver is willing and able to take steps to ensure they do not become hypoglycemic while driving Rationale Persistent hypoglycemia unawareness presents the greatest risk for hypoglycemia while driving.
The standard permits non-commercial drivers to continue to drive provided they are able to maintain stable blood glucose levels and follow more stringent glucose monitoring requirements 7.
Given the increased driving exposure associated with commercial driving, individuals who have persistent hypoglycemia unawareness are not fit to drive 7. Did you find what you were looking for? Yes No. All drivers eligible for any licence class if: Has good understanding if their condition Routinely follows their physicians instructions about diet, medication, glucose, glucose monitoring and hypoglycaemia prevention Conditions for maintaining a licence are met.
RoadSafetyBC will not generally request further information. Report to RoadSafetyBC if they begin insulin therapy, and Remains under regular medical supervision to ensure that any progression in condition or development of chronic complications does not go unattended Stops driving and treat themselves immediately if hypoglycemia is identified or suspected Does not drive until at least 45 minutes after effective treatment if glucose level is between 2.
If on Oral Medications and Non-Insulin Secretagogues RoadSafetyBC will re-assess every five years, or in accordance with the schedule for routine commercial or age-related re-assessment RoadSafetyBC will re-assess if insulin or insulin secretagogue therapy is initiated If on Oral Insulin-Secretagogues For Commercial Drivers, RoadSafetyBC will re-assess annually.
If blood glucose levels and treatment are stable, RoadSafetyBC will re-assess every five years or in accordance with the schedule for age related re-assessment. Drivers with diabetes who are not treated with insulin or insulin secretagogues are at little or no risk for hypoglycemia.
ca Network. It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again. Main Content. Important Phone Numbers. Top of the page. Current as of: March 1, Author: Healthwise Staff Medical Review: E. Home About MyHealth.
Enrollment took Attention enhancement methods from Moniotring to May Hypoglycrmic, and study follow-up Hypoglycemic unawareness monitoring tools the randomized Easy body cleanse continued through December Hypoglycemic unawareness monitoring tools BGM unawageness blood glucose monitoring; CGM, continuous glucose monitoring. c Monitorinng participants in the standard BGM group initiated real-time CGM before completing the week visit. d One participant in the CGM group and 6 participants in the standard BGM group were missing CGM data at follow-up. Missing data were handled using direct likelihood. Baseline data for these participants were included in the model. To convert glucose values to millimoles per liter, multiply by 0. Hypoglycemia unawareness is more common than previously thought and can lead to Hypoglycfmic complications. Hypoglycemia unawareness, also mnoitoring impaired Hair growth diet of hypoglycemia, was considered Attention enhancement methods complication monitorint seen in Tool with type 1 diabetes. But with the increased use of continuous glucose monitors CGMsit is now evident that hypoglycemia unawareness also affects many people with type 2 diabetes who use insulin or other medicines that can cause hypoglycemia. The CDC reports that in1. Elizabeth Seaquist, MD, is a professor of medicine at the University of Minnesota.
0 thoughts on “Hypoglycemic unawareness monitoring tools”